Many marketed Pharmaceuticals are known to cause idiosyncratic agranulocytosis in humans. Similarly prinomide, an antiinflammatory drug, was associated with a low incidence of agranulocytosis (<0.3%) in clinical trials, even though chronic toxicity studies in rodents and primates showed no evidence of agranulocytosis with either prinomide or its parahydroxy metabolite, CGS 12094. To investigate mechanisms for this human specific toxicity, experiments were conducted to study the metabolism of prinomide and CGS 12094 by myeloperoxidase (MPO), a major enzyme of neutrophils and leukocyte progenitor cells. Although prinomide was not metabolized by human MPO, CGS 12094 was rapidly metabolized (>90%; 2 min); this reaction was dependent on H 2 O 2 and MPO and was inhibited by azide. During the MPO-catalyzed metabolism of CGS 12094, reactive intermediates that irreversibly bound to protein and cysteine were generated. One of the reactive metabolites generated was identified by mass spectroscopy and trapping with cysteine as 1,4-benzoquinone, a compound implicated in the myelotoxicity associated with benzene. Thus during conditions which lead to elevated levels of H 2 O 2 (e.g., active inflammation), CGS 12094 is rapidly metabolized by MPO to reactive intermediates that may be related to prinomide-induced O 1997 Soetely of Toxicology.
agranulocytosis resulted in an immediate termination of clinical trials and a halt to any further development of this drug.
Prinomide was shown to be extensively metabolized in humans to at least six oxidative metabolites, the major being CGS 12094 (Fig. 1) , a pharmacologically active parahydroxy metabolite (Egger et ai, 1988; Kochak et ai, 1993) . During safety evaluation studies, prinomide and CGS 12094 were administered separately to rodents, dogs, and monkeys for periods up to 1 year. The results of these animal studies demonstrated findings comparable to otiier nonsteroidal antiinflammatory drugs (Green et ai, 1983) and indicated no treatment-related blood or bone marrow abnormalities. Thus, classical animal models were not predictive of idiosyncratic agranulocytosis, a human-specific toxicity shared by a number of marketed compounds, e.g., captopril, clozapine, and procainamide (Uetrecht, 1988 (Uetrecht, , 1989a (Uetrecht, , 1990 Eastmond and Smith, 1990; Fischer et ai, 1992) .
Currently, no preclinical model exists for predicting human drug-induced idiosyncratic agranulocytosis; however, an association between compounds causing this reaction and those that are metabolized by myeloperoxidase (MPO) has been recently made. MPO is a major enzyme system of neutrophils and granulocytic cells of bone marrow and has the potential to metabolize xenobiotics to reactive intermediates that are capable of binding to cellular macromolecules (i.e., DNA, proteins) and altering normal cell function (O'Brien et ai, 1988a,b; Uetrecht, 1988 Uetrecht, , 1989 Smith et ai, 1989; Eastmond and Smith, 1990; Schlosser et ai, 1990; Van Zyl et ai, 1990) . The working hypothesis (Fig. 2) is that drug-induced agranulocytosis can develop in a small number of individuals who (a) are able to produce a relatively high level of the MPO-catalyzed toxic metabolite(s), (b) are unable to detoxify the reactive intermediate(s) formed, and/or (c) have a compromised hematopoietic/immune system (i.e., are functionally predisposed to an agranulocytic reaction).
CGS 12094, in common with other peroxidase substrates, contains a phenol moiety Schlosser et ai, 1989 Schlosser et ai, , 1990 Smith et ai, 1989) . We hypothesized that the phenol moiety may be a substrate for MPO and thus may possibly be implicated in the agranulocytosis observed with prinomide. The current study was conducted to determine if CGS 12094 could act as a substrate for human MPO and to investigate the nature of any products generated during the MPO-catalyzed metabolism of this compound. It was hoped that the information generated from the study would help in the understanding of prinomide-induced agranulocytosis and would begin to provide information necessary for the development of preclinical test systems to evaluate compounds for their potential to elicit an idiosyncratic agranulocytic reaction in humans.
METHODS

Materials.
Prinomide and CGS 12094 were specifically labeled with I4 C at the carbonyl and nitrile groups, respectively (Fig. 1) . Labeled compounds, unlabeled prinomide (CGS 10787B-triethanolamine salt or CGS 10787D-tromethamine salt), and unlabeled CGS 12094 were dissolved in 100% ethanol (10 mM) and diluted in 0 I M sodium phosphate buffer, pH 7.2, immediately before use. Purified human neutrophil MPO (>97% pure) was purchased from Elastin Products Company, Inc. (Owensville, MO) and reconstituted with 0.1 M sodium phosphate buffer, pH 7.2. All other reagents and/or chemicals were purchased from suitable manufacturers.
Compound metabolism-Spectrophotometric analysis. A single, nonsaturating dose of CGS 12094 (50 IIM) or prinomide was chosen as this concentration was optimal for absorbance measurements and within the range detected in blood samples from clinical trials (Kochak et at.. 1993) . Complete reactions contained compound, MPO (20 /zg/ml), and H 2 O 2 (0.1 mM). All incubations, unless otherwise noted, were performed in 01 M sodium phosphate buffer, pH 7.2, for 0-2 min at 37°C. Spectrophotometric readings (326 nm) were recorded at several time points after the addition of H 2 O 2 to the reaction mixture CGS 12094 metabolism by MPO-HPLCanalysis.
Reactions were carried out as described above for spectrophotometric analysis except that reactions were terminated by the addition of TCA (5% final concentration) or by injecting the sample onto a \0-fiM Waters CI8 liBondapak column (3.9 X 300 mm) equipped with a guard column. The column was eluted with methanol/acetonitrile/50 mM acetate buffer, pH 4.5. at a flow rate of I ml/min, unless otherwise noted. Column effluent was monitored using a Waters 484 UV detector at 254 or 305 nm. I4 C]CGS 10787B was incubated with MPO (20 /zg/ml) and 2 mg/ml BSA in 0.1 M phosphate buffer. pH 7.2, at 37°C for 5 min. Reactions were initiated by the addition of H 2 O 2 (0.5 mM) and incubations were continued for up to 60 min. Reactions were terminated by the addition of ice-cold TCA (5% final concentration). TCA precipitable material was washed twice with acetone, hexane/acetone (1:1), and methanol/acetone (1:1) and the samples were air dried. Pellets were resolubilized in 1 ml of 0 1 M NaOH at 70°C for 60 min and then neutralized with 20 /zl of concentrated HC1. Half of each sample was added to 5 ml of Beckman Readysafe scintillation cocktail and radioactivity was measured by liquid scintillation spectroscopy .
Measurement
Synthesis of the monocysteine conjugate of 1-4-benzoquinone. The synthesis of 1,4-benzoquinone-monocysteine conjugate was based on the method of Lunte and Kissinger (1984) as modified by . 1,4-Benzoquinone (10 mM in 0.1 M sodium phosphate buffer, pH 7.2) was slowly mixed with cysteine (10 mM in 0.1 sodium phosphate buffer, pH 7 2) over a 30-min period at room temperature. A sample was injected onto a 10-IZM Waters C18 /zBondapak column (3.9 X 300 mm) equipped with a guard column and eluted with acetonitrile. 50 mM acetate buffer, pH 4.5 (5:95), at a flow rate of 1 ml/min. Column effluent was monitored with a Waters 484 UV detector at 305 nm. Under these conditions a major peak was identified with a retention time of 7.6 min, characteristic of the monocysteine conjugate of 1,4-benzoquinone.
Mass spectroscopic analysis. CGS 12094 (50 IZM), 20 /zg/ml MPO, 100 mM NaCl, and 0.1 mM H 2 O 2 in 0.1 M sodium phosphate buffer, pH 7 2, were incubated at 37°C. After 3 min of incubation, an additional 5 /zl CGS 12094 (20 mM), 2.5 /zl MPO (5 /zg), 2.5 /zl sodium chloride (5 M), and 10 izl H 2 O 2 (18.6 mM) was added to the reaction then incubated for an additional 3 min. This step was repeated an additional three times. HPLC analysis of the final sample resulted in a chromatogram comparable to that obtained with a complete sample (i.e., 50 nmol CGS 12094) However, peak areas were increased approximately fivefold. The sample was extracted three times with ethyl acetate (1:1) and analyzed by electron impact mass spectroscopy. 
MYELOPEROXIDASE METABOLISM
RESULTS
CGS 12094 Metabolism by MPO
The metabolism of CGS 12094 by MPO in the presence of H 2 O 2 was monitored via spectrophotometric methods by measuring the decrease in absorbance of CGS 12094's 326-nm peak (Fig. 3 ). This change in UV absorbance permitted the measurement of CGS 12094 metabolism under a variety of different reaction conditions. CGS 12094 was also metabolized when a physiological concentration of chloride was present in the complete reaction system; however, the resulting spectrum change at 326 nm was different than that generated in the chloride-free system, which suggests that different metabolites were formed in the presence of chloride.
The metabolism of CGS 12094 was dependent on the presence of both MPO and H 2 O 2 and was inhibited when MPO was preincubated with sodium azide or ascorbic acid (in vitro peroxidase inhibitors) prior to the addition of CGS 12094 and H 2 O 2 to the reaction (Fig. 4A ). Hydroquinone, shown to be an effective cosubstrate for peroxidases , also inhibited the metabolism of CGS 12094 when preincubated with MPO prior to the addition of CGS 12094 and H 2 O 2 to the reaction mixture (Fig. 4A ). The addition of DETAPAC (diethylenetriamine pentacetic acid), an iron chelator, to reactions containing CGS 12094, MPO, and H 2 O 2 did not inhibit CGS 12094 metabolism (Fig.  4A ). When sodium chloride was present in the reactions, results similar to those described above were obtained, except that ascorbic acid did not inhibit the MPO-catalyzed metabolism of CGS 12094 (Fig. 4B ). An increase or decrease in CGS 12094 concentration with a concomitant change in the concentration of the cosubstrate, H 2 O 2 , resulted in ab- . UV absorbance spectra of CGS 12094. The complete system contained 50 /IM CGS 12094, 20 ^g/ml MPO, and 0.1 mM H 2 O 2 and was incubated at 37°C for 2 min. The spectra of CGS 12094 were equivalent to the spectra of the complete system without either H 2 O 2 or MPO. In systems containing sodium chloride, the final concentration was 100 mM.
sorbance spectra similar to those described above (data not shown).
Data collected using HPLC methodology to monitor CGS 12094 metabolism demonstrated that CGS 12094 is essentially completely metabolized in the presence of MPO and H 2 O 2 after a 2-min incubation (Fig. 5) . HPLC analyses also indicated that during spectrophotometric analysis at 326 nm, the 10-20% of initial absorbance remaining after a 2-min incubation with CGS 12094, MPO, and H 2 O 2 was due to CGS 12094 metabolites and not the presence of unmetabolized CGS 12094 (data not shown). Prinomide was not metabolized by MPO under any of the conditions used for CGS 12094.
Formation of Reactive Metabolites
Initial experiments to determine if reactive metabolites were generated from the metabolism of CGS 12094 by MPO were accomplished by reacting [ I4 C]CGS 12094 with MPO under varying reaction conditions in the presence of BSA and determining the amount of irreversibly bound radioactivity associated with the TCA-precipitated material, using liquid scintillation spectroscopy. MPO-catalyzed metabolism of [
14 C]CGS 12094 resulted in the binding of [ 14 C]CGS 12094 equivalents to BSA in a time-dependent mariner which reached maximum at 30 min (Fig. 5) . However, since the metabolism of CGS 12094 in the presence of BSA was rapid, greater than 90% metabolized within the first 2 min of incubation as determined by HPLC analysis (Fig. 5) , this implies that at least some of the reactive metabolites formed were relatively stable (i.e., reacted slowly with BSA).
The generation of reactive metabolites was dependent upon the presence of both MPO and H 2 O 2 as the absence of either resulted in minimal binding of CGS 12094 to BSA (Fig. 6) 
Analysis of CGS 12094 Metabolites
Incubation of CGS 12094 with MPO and H 2 O 2 resulted in the formation of two major peaks as detected by LTV absorbance at 254 nm (Fig. 7) . Both peaks were reduced when BSA was present in the reaction or if cysteine was (Fig. 8A) , none of which coeluted with the peaks generated in a chloride free system (Fig. 7) . The formation of the major peak (asterisks in Figs. 7 and 8A) with a retention time of approximately 315 sec was reduced when the reaction was carried out in the presence of BSA (Fig. 8B ) or when cysteine (Fig. 8C ) was added to the sample. This peak was shown to coelute with authentic 1,4-benzoquinone under three different mobile phase conditions. Subsequent analysis of this peak by mass spectroscopy confirmed its identification as 1,4-benzoquinone. In addition, a peak that coelutes with a synthetic 1,4-benzoquinone-monocysteine conjugate was detected in reaction mixtures incubated with cysteine (Fig. 9) . The final concentration of 1,4-benzoquinone generated from the MPO-catalyzed metabolism of CGS 12094 (50 fiM) by MPO in the presence of chloride was determined by HPLC to be 17.7 ± 3.2 ^M (mean ± SD, N = 10) or approximately 35% of the initial concentration of CGS 12094.
DISCUSSION
Drug-induced idiosyncratic agranulocytosis in humans is characteristic of a variety of different therapeutic agents. Although the mechanism(s) responsible for this phenomena is not well known, information emerging from the literature indicates a relationship between drugs causing agranulocytosis and the ability of these drugs (or their metabolites) to act as reducing substrates for MPO or the oxidants (e.g., hypochlorous acid) produced by this reaction (Wasil et ai, 1987; Uetrecht, 1988 Uetrecht, , 1989a Uetrecht, ,b, 1990 Uetrecht and Zahid, 1988; Eastmond and Smith, 1990; O'Brien et ai, 1991) . Furthermore, the metabolism of xenobiotics by MPO has been shown to result in the formation of reactive metabolites capable of binding to macromolecules and thus possibly affecting normal cellular function (Uetrecht, 1988 (Uetrecht, , 1989a Smith et al., 1989; Schlosser et al., 1990) .
Several factors led us to investigate the role of CGS 12094 in the idiosyncratic agranulocytosis associated with prinomide administration, including its long half-life in humans (4 days; Kochak et al., 1993) and its phenol moiety, a characteristic peroxidase substrate Schlosser et al., , 1990 . The study presented was conducted to determine if CGS 12094 was a substrate for MPO and to characterize the products generated from this reaction in an attempt to understand the relationship between these metabolites and the development of the agranulocytosis associated with prinomide administration. HPLC analysis of metabolites generated by the MPO-dependent metabolism of CGS 12094 (254 nm). The complete system contained (A) 50 fM CGS 12094, 20 tig/ml MPO, and 0.1 mM H 2 O 2 ; (B) in 100 mM NaCl. Samples were incubated for 2 min at 37°C. A peak that coeluted with authentic 1,4-benzoquinone is designated by an asterisk. The concentration of 1,4-benzoquinone generated in the complete system with chloride was 17.7 ± 3.2 /JM (mean ± SD, N = 10) or approximately 35% of the initial concentration of CGS 12094. was catalyzed by MPO and not the result of oxidative breakdown due to the interaction of free iron or heme in the reaction with H 2 O 2 .
In contrast to CGS 12094, prinomide was shown not to be a substrate for MPO in this study. Since prinomide was not a substrate for these peroxidases, reactive metabolite formation from the interaction of prinomide with MPO was not detected in these binding assays.
HPLC analyses demonstrated that different metabolites are formed in a system with chloride compared to a chloride free system. This suggests a role for the hypochlorous acid, which is produced in a system containing chloride, in the metabolism of CGS 12094, and as demonstrated with other xenobiotics, such as phenytoin, hydralazine, dapsone, propythiouracil, and aminopyrine (Wasil et ai, 1987; Uetrecht and Zahid, 1988; O'Brien et al., 1991) . Ascorbic acid, shown to inhibit CGS 12094 metabolism in a chloride-free system, did not inhibit CGS 12094 metabolism in reactions containing chloride. Since ascorbic acid has been shown to reduce only MPO Compound II (Fe 4+ ) back to native MPO (Fe 3+ ), this compound would not be expected to inhibit the production of hypochlorous acid that results from the conversion of MPO Compound I (Fe 3+ ) directly back to native MPO (Bolscher et ai, 1984; Marquez et ai, 1990 ) and implies that hypochlorous acid could be involved in the metabolism of CGS 12094 in systems with chloride. However, preliminary data (not published) indicate that neither CGS 12094 nor the metabolites formed in the absence of chloride is broken down by hypochlorous acid up to concentrations of 100 /J,M and suggest the possibility that the metabolism of CGS 12094 by MPO in a system with chloride was the result of a more involved interaction of CGS 12094 with a MPO-chloride or MPO-hypochlorous acid complex. In addition, due to the idiosyncratic nature of this xenobiotic-induced agranulocytosis and the inability to reproduce this finding in laboratory animals, the determination of which metabolites(s) is responsible for the effect can only by hypothesized at this time.
HPLC analyses of the metabolites generated by the metabolism of CGS 12094, in the presence of a physiological concentration of chloride, indicated that a major metabolite was generated and identified as 1,4-benzoquinone. The identity of this metabolite peak was confirmed by mass spectroscopy as well as the detection of a 1,4-benzoquinone-monocysteine conjugate in samples with cysteine. Based on the structure of CGS 12094 and the identification of 1,4-benzoquinone as a metabolite, a proposed pathway for the formation of 1,4-benzoquinone as well as the 1,4-benzoquinonemonocysteine conjugate is shown in Fig. 10 . This pathway is similar to that proposed by O'Brien et ai (1991) for the MPO-catalyzed metabolism of a structurally similar compound, acetaminophen. To date, 1,4-benzoquinone has been the only CGS 12094 metabolite to be identified thus far. Based on the pathway proposed for acetaminophen, chlorinated CGS 12094 metabolites could also be present.
1,4-Benzoquinone has been implicated as the metabolite responsible for the myelotoxicity associated with benzene administration (Eastmond et ai, 1987; Smith et ai, 1989 , Pirozzi et ai, 1989 Thomas et ai, 1990) . Some of the cellular effects of 1,4-benzoquinone include interference with microtubule assembly and the inhibition of DNA and RNA synthesis, mitosis, and growth of bone marrow stromal cells, cells responsible for supporting the growth and maturation of granulocytic cells (Smith et ai, 1989; Thomas et ai, 1989 Thomas et ai, , 1990 .
While 1,4-benzoquinone formation from the metabolism of CGS 12094 suggests that this compound could be implicated in the agranulocytosis associated with prinomide administration in humans, the contribution of other metabolites cannot be ruled out. Radiolabeled studies of the metabolism I4 C]CGS 12094, the binding detected in these assays does not account for the 1,4-benzoquinone generated. This indicates that a substantial amount of reactive metabolites other than 1,4-benzoquinone were formed, suggesting that a variety of reactive metabolites could contribute to the development of agranulocytosis.
The metabolite(s) generated by the MPO-catalyzed oxidation of drugs could lead to the formation of agranulocytosis by two different proposed mechanisms. First, the metabolites could simply be toxic to neutrophils, bone marrow cells (i.e., cells of the granulocytic lineage), and/or the stromal cells which support the growth and maturation of the granulocytic cells (Fig. 2) (Heimpel 1988; Smith et ai, 1988; Uetrecht, 1988 Uetrecht, , 1989 Uetrecht, , 1990 . 1,4-Benzoquinone, a metabolite of benzene, and shown in this in vitro study to be a metabolite of CGS 12094, has been shown to interfere with granulopoiesis in bone marrow cultures through a cytotoxic mechanism directed against the granulocytic cells themselves and/or stromal cells (Smith et at, 1988) . However, a cytotoxic event would not be expected to produce a low incidence (<0.3%) of agranulocytosis as seen with prinomide administration or be idiosyncratic in nature (Heimpel, 1988; Uetrecht, 1989b) .
A second possible mechanism for the generation of agranulocytosis is an immune-mediated mechanism (Heimpel, 1988 , Uetrecht, 1989a Hofstra et al, 1992) . Reactive metabolite, generated during the MPO-mediated metabolism of a drug, by binding to a cellular macromolecule of the neutrophil, could act as a hapten or immunogen and result in the production of antibodies and the possible rapid destruction of circulating cells and bone marrow cells that express an antigenic determinant similar to the hapten (Fig. 2) . While the destruction of bone marrow cells by antibodies is a possibility, many patients with agranulocytosis in which "antidrug" antibodies have been detected, exhibit bone marrow conditions characterized by hypercellularity of the granulopoietic lineage and maturation arrest suggesting that only peripheral destruction of neutrophils is occurring (Heimpel, 1988) . Even though 1,4-benzoquinone has been shown to be a myelotoxic compound, the production of 1,4-benzoquinone and/or other CGS 12094 metabolites in the neutrophil and subsequent binding to cellular macromolecules, thus forming a hapten, would suggest that an immune-mediated mechanism for prinomide-induced idiosyncratic agranulocytosis is possible as well (Fig. 2) .
The characterization of prinomide-induced idiosyncratic agranulocytosis as a cytotoxic event or an immune-mediated response may prove to be difficult. The matter is further complicated by factors that influence the development of agranulocytosis, such as differences in drug metabolism, detoxification mechanisms, immune status, and physical conditions existing among individual patients and between humans and animals. However, one common event that appears to be required for both pathways is the generation of reactive metabolites capable of binding to cellular macromolecules (Fig. 2) . Thus during conditions which lead to elevated levels of H 2 O 2 (e.g., active inflammation), CGS 12094 may be rapidly metabolized by MPO to reactive intermediates that may be involved in prinomide-induced agranulocytosis.
Based on this study and the current literature, the ability of a compound to act as a substrate for myeloperoxidase and subsequently generate reactive metabolites may represent an important step in the development of human idiosyncratic agranulocytosis. Information from these studies and future in vitro studies with isolated neutrophils and bone marrow cultures, and in vivo studies with DBA/2 mice, a strain sensi-tive to bone marrow toxicants, may provide the necessary information for the development of possible assays for screening compounds for their potential to elicit an idiosyncratic reaction in humans.
